Navigation Links
Suven Life Sciences Presenting Pre-clinical data of their,NCE’s SUVN-502 and SUVN-507at International Brain Research,Organization (IBRO) 2007 World Congress of Neuroscience

HYDERABAD, India, July 5th, 2007 – Several data presentations from Suven’s portfolio of investigational neuroscience compounds will be presented at International Brain Research Organisation (IBRO) 2007 World Congress of Neuroscience to be held at Melbourne, Australia during July 12-17, 2007.

Scientists from Suven Discovery Research will be presenting new data for 4 promising areas of neuroscience viz. Alzheimer’s, Schizophrenia, Parkinson and Obesity diseases. These areas present significant unmet medical need for which current treatment options are insufficient. Suven has a number of programs in each of these areas, focusing on novel approaches that may lead to the development of new therapies for patients.
Suven is presenting the data on their leading preclinical candidates SUVN-502 and SUVN-507 at IBRO 2007 world congress of Neuroscience .

Suven is committed to neuroscience research and for development of new treatments for neurological disorders. Suven’s discovery research focuses on Central Nervous System (CNS) disorders through novel mechanisms using small-molecule medicinal chemistry approaches. Suven’s CNS drug discovery scientists at Hyderabad, India are pursuing innovative ways to develop treatments for a variety of CNS disorders like Alzheimer's, Schizophrenia, Depression, Cognitive disorders and Neurodegeneration.

Suven Life Sciences, a Hyderabad based Life Sciences Company, pioneer in Contract Research And Manufacturing Services (CRAMS) since 1995 in its endeavor to become collaborative research partner (CRP) for global life science companies has embarked on new business model “Drug Discovery and Development Support Services” (DDDSS) with the onset of Intellectual Property Regime in India since January 2005.

A focused provider of DDDSS for development of New Chemical Entities to life sciences companies, Suven
'"/>




Page: 1 2

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
4. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. Answerthink and LORENZ Life Sciences Group Announce Strategic Alliance for the SAP Life Science Industry
7. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
8. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
9. Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon
10. Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference
11. IR BioSciences Announces Promising Data from Study of Its Compound Homspera

Post Your Comments:
(Date:11/19/2009)... , ARDEE, Ireland, Nov. 19 W...d the pricing of its previously announced secondar... a price to the public of $22.25 per share. The s...Bain Capital Partners, DLJ Merchant Banking, J.P. ...as H. Lee Partners, L.P., certain other institutio...
(Date:11/19/2009)... , MOUNTAIN VIEW, Calif., Nov. 19 /PRNewswire...q: ALXA ) announced today that its corporate pres...al Piper Jaffray Health Care Conference on Wednesd...he presentation will be webcast from The New York ...Thomas B. King, Alexza President and CEO. ,, ...
(Date:11/19/2009)... , Part of International Internet Week of...wire-USNewswire/ -- The U.S. Food and Drug Adminis...nternational effort, called the International Inte...al actions involving medical products. ,, (Logo...ALOGO ) ,, During the effort, the FDA,s Office ...
Breaking Medicine Technology:Warner Chilcott Prices Secondary Equity Offering 2Warner Chilcott Prices Secondary Equity Offering 3Warner Chilcott Prices Secondary Equity Offering 4Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 2Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 3UPDATE: FDA Issues 22 Warning Letters to Web site Operators 2Biocartis Raises EUR10 Million in Series A Financing Round 5498 1Biocartis Raises EUR10 Million in Series A Financing Round 5498 2Biocartis Raises EUR10 Million in Series A Financing Round 5498 3Cord Blood America Details Las Vegas Laboratory Progress in Analyst Interview 5496 1Cord Blood America Details Las Vegas Laboratory Progress in Analyst Interview 5496 2Cord Blood America Details Las Vegas Laboratory Progress in Analyst Interview 5496 3Clinical Force Announces that Stiris Research has Selected the Clinical Force CTMS to Manage Clinical Trials 14476 1Clinical Force Announces that Stiris Research has Selected the Clinical Force CTMS to Manage Clinical Trials 14476 2Clinical Force Announces that Stiris Research has Selected the Clinical Force CTMS to Manage Clinical Trials 14476 3
... England, April 21 Circassia Ltd, a specialty,bio...ed today that it has,initiated a phase II clinical...patients with asthma. The trial builds on positive...clinical benefits of ToleroMune allergy,therapy, a...llergy-associated,asthma. , The lastest study,...
...2905 , , DENVER, April 20 Scientists from the Ba...ay presented data at the American Association for ...epresents significant research advancements in the...e breast cancer. , , (Logo: http://www.newscom.c...nos researchers discovered that when an FDA-approv...
Other Medicine Technology:Circassia's Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients 2Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference 2Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference 3
(Date:11/20/2009)...otentially adding to preemie delivery rate, expert...s) -- Recent reports show that the rate of preterm...s. Now, a new study suggests one reason why: Many...term birth in the first place. , About one-quar...d a baby born at 34 to 36 weeks of gestation to be...
(Date:11/20/2009)...n with seasonal flu , , FRIDAY, Nov. 20...rting that children with asthma are more likely to...u. , "Asthma has been identified as a significa...fluenza, present in 21 percent to 30 percent in th...w researchers from the Hospital for Sick Children ...
(Date:11/20/2009)...warns against the new breast cancer recommendation...Force. These guidelines may be cost-effective, but... wrong to be safe than sorry? , ...ce recommendations, published in the current issue... firestorm in the medical community. Major medical...
(Date:11/20/2009)...wswire/ -- Missouri state employees in the Southwe...e the option to choose Mercy Health Plans thanks t...nsolidated Health Care Plan (MCHCP) and Mercy Heal...ssouri regions include the following counties: Bar...s, Greene, Hickory, Howell, Jasper, Laclede, Lawre...
(Date:11/20/2009)...0 California minority advocacy gro...he Wall/Las Memorias, Latina Breast Cancer Agency,... Real Medicine Foundation today sent a letter to B... reconsider harmful and discriminatory coverage po...ly calls for an end to the practice of step therap...
Breaking Medicine News(10 mins):Health News:Many Women Miscalculate Time to Full-Term Birth 2Health News:Many Women Miscalculate Time to Full-Term Birth 3Health News:Many Women Miscalculate Time to Full-Term Birth 4Health News:New Breast Cancer Recommendation May Cost Lives While Saving Money 2Health News:New Breast Cancer Recommendation May Cost Lives While Saving Money 3Health News:Missouri Consolidated Health Care Plan Provides Mercy Health Plans Option 2Health News:California Minority Advocacy Groups Send Letter to Blue Shield of California Calling for an End to Discriminatory Practice that Denies Patients in Pain Access to Proper Medication 2Health News:California Minority Advocacy Groups Send Letter to Blue Shield of California Calling for an End to Discriminatory Practice that Denies Patients in Pain Access to Proper Medication 3Health News:California Minority Advocacy Groups Send Letter to Blue Shield of California Calling for an End to Discriminatory Practice that Denies Patients in Pain Access to Proper Medication 4
...earchers in the US felt that artistic skill is oft...nown how the brain influences artistic creativity....oke, dementia, or trauma// - would destroy your ab...visual art, fared when they suffered some kind of ...
...ording to pshycologists, believing that one can c...ur heart and circulation.// Exposure to a stressfu...use it increases blood pressure and resistance to ...moderated by many psychological factors, such as p...
...roup scientists have recently helped the Communica...re strain of cholera, which wreaked havoc in coast...athogen, transmitted through sea food, has become ...ns made the discovery. “We received calls from the...
...rological diseases seen in people who were student...y to develop. Amyotropic lateral sclerosis (ALS)//...tion. It's sometimes known as Lou Gehrig's disease...ng ALS, as well as motor neurone disease, which is...
...ording to a notice distributed by the agency, the ... United Therapeutics Corp.'s pulmonary arterial hy.... A spokesperson for the FDA told Reuters Health t...ting clearance based on an effect// on a surrogate...
...ording to new study some light was thrown on the v...ted by the condition. The study focuses on the ris.../ At least 2 percent of the population is born wit...hat eye. Some, but not all, countries place high i...
Other Medicine News:
P-66
P-1066-A-SS
P-1065-SS
Mobile Instrument Stand
Medicine Products: